Paper Details

  1. Home
  2. Paper Details

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.

Author: BlackJed, BoganRichard K, ChenAbby, DauvilliersYves, Del Rio VillegasRafael, Foldvary-SchaeferNancy, PartinenMarkku, SkobierandaFranck, SkowronskiRoman, ThorpyMichael J, ŠonkaKarel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lower-sodium oxybate (LXB) was found to effectively improve cataplexy and excessive daytime sleepiness in individuals with narcolepsy. This study further analyzes data from a previous trial exploring the clinical course and feasibility of transitioning from other anticataplectics to LXB monotherapy.
Paper Details　
Original Abstract of the Article :
Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people with narcolepsy in a placebo-controlled, double-bli...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213292/

データ提供：米国国立医学図書館（NLM）

Lower-Sodium Oxybate: A New Hope for Cataplexy?

This research dives deep into the world of narcolepsy, a sleep disorder characterized by sudden bouts of muscle weakness called cataplexy. The study focuses on a promising medication called lower-sodium oxybate (LXB), which is a cousin of sodium oxybate (SXB) with a unique twist - it contains 92% less sodium. Researchers are looking to see if LXB can successfully tackle cataplexy and excessive daytime sleepiness in individuals with narcolepsy. They conducted a double-blind, randomized withdrawal study (NCT03030599) to compare LXB with a placebo. The results are quite encouraging, with LXB proving to be a promising treatment option for cataplexy. The study also delves into the feasibility of switching from other medications to LXB monotherapy, offering a potential solution for those with narcolepsy who have struggled to find effective treatments.

A Light at the End of the Tunnel for Narcolepsy

The study's findings suggest that LXB might be a more effective alternative to SXB for treating cataplexy. This could be a game-changer for those with narcolepsy, who often face challenges in managing their condition. The study's exploration of transitioning to LXB monotherapy is particularly intriguing as it opens doors for individuals who have not found success with conventional treatments.

Living with Narcolepsy

If you or someone you know is living with narcolepsy, it's important to stay informed about the latest research and treatment options. It's crucial to work with a healthcare professional to find a treatment plan that best suits your individual needs.

Dr.Camel's Conclusion

This study highlights the promising potential of lower-sodium oxybate as a treatment for cataplexy in narcolepsy. Like a camel traversing the vast desert searching for an oasis, researchers are relentlessly exploring new avenues to improve the lives of individuals with this challenging sleep disorder.

Date :
  1. Date Completed 2022-06-08
  2. Date Revised 2022-08-29
Further Info :

Pubmed ID

35635687

DOI: Digital Object Identifier

PMC9213292

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.